Advancing Chinese Academy of Sciences' efforts in trailblazing medical research in regenerative medicine, CRMH is leveraging Hong Kong’ s various capabilities and advantages in biomedical sector to set up “Hong Kong standards” for clinical applications of regenerative medicine, including “Good Manufacturing Practice (GMP)” for products that will be accredited and recognised internationally.

In the long run, CRMH is looking forward to fostering regional collaborations in biomedicine and health through China’s Belt and Road Initiative and advancing biomedical research and development to solve key problems in public health in the Greater Bay Area.

Please contact us to discuss potential collaboration opportunities in R&D or commercial partnerships.